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Neuraminidase Inhibitors (NI) are currently the most effective drugs against influenza. Recent cases of NI resistance are
a cause for concern. To assess the danger of NI resistance, a number of studies have reported the fraction of treated
patients from which resistant strains could be isolated. Unfortunately, those results strongly depend on the details of
the experimental protocol. Additionally, knowing the fraction of patients harboring resistance is not too useful by
itself. Instead, we want to know how likely it is that an infected patient can generate a resistant infection in a
secondary host, and how likely it is that the resistant strain subsequently spreads. While estimates for these
parameters can often be obtained from epidemiological data, such data is lacking for NI resistance in influenza. Here,
we use an approach that does not rely on epidemiological data. Instead, we combine data from influenza infections of
human volunteers with a mathematical framework that allows estimation of the parameters that govern the initial
generation and subsequent spread of resistance. We show how these parameters are influenced by changes in drug
efficacy, timing of treatment, fitness of the resistant strain, and details of virus and immune system dynamics. Our
study provides estimates for parameters that can be directly used in mathematical and computational models to study
how NI usage might lead to the emergence and spread of resistance in the population. We find that the initial
generation of resistant cases is most likely lower than the fraction of resistant cases reported. However, we also show
that the results depend strongly on the details of the within-host dynamics of influenza infections, and most
importantly, the role the immune system plays. Better knowledge of the quantitative dynamics of the immune
response during influenza infections will be crucial to further improve the results.
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Introduction
Neuraminidase Inhibitors (NI) are currently the most
effective drugs against inﬂuenza [1]. They also constitute an
important component of control strategies against a potential
pandemic [2]. However, cases of NI resistance have already
been reported, for both currently circulating human inﬂu-
enza [3] and the avian H5N1 strain [4]. Mathematical models
and computer simulations have been used to study how NI
treatment or prophylaxis might affect the spread of resistance
in a population [5–8]. The accuracy of the predictions
obtained from these studies depends on the accuracy of the
estimates for the parameters governing the model dynamics.
Two important parameters, for which there are currently
no good estimates, are: (i) the initial generation of resistance,
deﬁned here as the number of resistant infections caused by a
patient receiving NI treatment who was initially infected with
a sensitive strain; (ii) the subsequent spread of resistance,
deﬁned as the number of resistant infections caused by a
patient initially infected with the resistant strain.
The best data we currently have for the generation of NI
resistance come from clinical studies that report the fraction of
treated patients from which resistant strains could be isolated
[9–13].Unfortunately, theresultsstronglydependonthe details
of the study, such as sensitivity of virus detection [3]. Further,
knowingthefractionofpatientsthatharborresistantvirusdoes
not directly lead to an estimate for the generation of resistance.
For the spread of NI resistant strains, some insights have
been obtained from studies with ferrets, where it was shown
that certain resistant strains are transmissible, while others
are not [14–16]. However, these studies currently do not
provide enough quantitative data to allow estimation of the
parameter governing the spread of resistance.
The dilemma is obvious: We need good parameter
estimates to understand and model the potential spread of
NI resistant inﬂuenza, but we do not want to wait until such
spread has occurred and epidemiological data are available
that would allow us to obtain good parameter estimates.
Therefore, it is important to ﬁnd alternative ways to estimate
these parameters.
Here, we use a conceptual framework that links within-host
infection dynamics to between-host epidemiological param-
eters [17–20]. We extend this framework and combine data
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matical models. We show how this approach can produce
estimates for the generation and spread of resistance, without
the need for epidemiological data. Our study also shows that
a better understanding of the within-host infection dynamics
of inﬂuenza is crucial if we want to obtain precise results
using this approach.
Materials and Methods
Deterministic Model of Infection Dynamics
The simplest way of modeling the dynamics of viral
infections is based on ordinary differential equations, an
approach that has a long and successful history [21,22]. The
basic model describes the dynamics of uninfected and
infected cells, and virus. In this model, virions infect target
cells (in the case of inﬂuenza, these are mainly epithelial cells
of the respiratory tract), leading to depletion of those cells
and subsequent decline in viral load. We use a version of this
simple model, which we refer to as the target cell depletion
(TD) model. A recent study showed that such a simple model
could ﬁt inﬂuenza viral load data [23].
This TD model does not include an immune response.
Since the immune response likely contributes to viral
clearance [24,25], we also use a second model that includes
an antibody-based immune response. We assume the anti-
body levels increase in the simplest way possible, through
growth at a constant rate, independent of viral load (similar
to the ‘‘programmed response’’ expansion found in T cells
[26]). This model, which we term the immune response (IR)
model, has more parameters than the TD model. The data we
use to ﬁt the models is not sufﬁcient to allow discrimination
between the two models; therefore, the IR model cannot be
justiﬁed on statistical grounds. However, since a large
number of studies have indicated the importance of immune
responses for viral clearance, we ﬁnd it important to also
study this model. The equations and parameters for the two
models are given in Tables 1 and 2. For general information
on models of this type, and their use to describe viral
infection dynamics, we refer the reader to the existing
literature [21,22].
Most parameter values for the two models are obtained by
ﬁtting viral load data from human volunteers [27]. We include
datapoints from the experimental study for which the 95%
conﬁdence interval is above the level of assay detection for a
single individual (see [27] for details). The data are shown as
symbols in Figure 1, together with the best ﬁt viral load
curves. The parameter values for the best ﬁts are given in
Table 2.
While we tried to obtain all parameters through ﬁtting, the
available data are not sufﬁcient to obtain reliable estimates.
We therefore decided to use estimates obtained from the
literature for those parameters where such information was
available. One parameter that we estimate from independent
experimental studies is the mutation rate, l, at which NI
resistant mutants are produced. The mutation rate per base
pair per replication for inﬂuenza A has been estimated to be
about 7310
 5 [28,29]. A more recent study reported the rate
to be about 2 3 10
 6 [30]. These studies come with
considerable uncertainty due to only a few observed mutation
events. Several mutations conferring neuraminidase resist-
ance have been identiﬁed [3,31]. Still, the number of possible
mutations that results in NI resistant, viable mutants is likely
small. If we estimate that number to be between 1 and 10, we
obtain a mutation rate in the range of about 10
 6 to 10
 4. For
most of our simulations, we choose l ¼ 10
 5. We also
investigate how variation in l affects the results.
Another independently estimated parameter is the cost in
ﬁtness, c. We assume that the dynamics of resistant virus is the
same as that of the drug-sensitive one, with the exception that
the virus production rate is lowered by 1 c. The parameter c
represents the ﬁtness cost that comes with being resistant.
(Similar results are obtained if we assume that resistance
reduces ﬁtness by lowering the infection rate b.) Several
studies have indicated that some NI resistant mutants have a
signiﬁcantly reduced ﬁtness, while others have ﬁtness similar
to the sensitive strain [14,16,31–33]. From recent in vivo
studies, one can obtain estimates for the ﬁtness cost. Fitting
the IR model to viral load data from ferrets that were infected
with either wild-type inﬂuenza or resistant mutants (see
Figure 5 in [16]), we obtained a ﬁtness cost of 49% for the
R292K mutant and a 9% ﬁtness cost for the E119V mutant
(see [16] for details on these mutants). To obtain conservative
results for our study, we chose the ﬁtness cost for the resistant
strain to be 10% (c ¼ 0.1). We also study how different values
of c inﬂuence the results.
The initial number of uninfected epithelial cells has been
Table 1. Equations for the Two Models Describing the within-
Host Dynamics
Equation Meaning
U ˙ ¼  bU(VsþVr) Uninfected cells
I ˙s ¼ bUVs dlIs Sensitive infected cells
I ˙r ¼ bUVr dlIr Resistant infected cells
V ˙s ¼ (1 a)(1 l)pIs dVVs kXVs Sensitive virus
V ˙r ¼ (1 a)lpIsþ(1 c) pIr dVVr kXVr Resistant virus
X ˙ ¼ rX Immune response
a ¼f 0 for t,T; a for t Tg Antiviral efficacy
doi:10.1371/journal.pcbi.0030240.t001
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Author Summary
Neuraminidase Inhibitors (NI) are currently the most effective drugs
against influenza. Recent cases of NI resistance are a cause for
concern. A number of studies have reported the fraction of treated
patients from which resistant virus could be isolated. While these
results provide some assessment of the danger of NI resistance, a
more quantitative understanding is preferable. We specifically want
to know how likely it is that an infected, treated patient infects
another person with the resistant strain, and how likely it is that the
resistant strain subsequently spreads. Knowing these quantities is
important for studies of the population-wide emergence of
resistance. While these parameters can often be estimated from
epidemiological data, such data is lacking for NI resistance in
influenza. Here, we use an alternative approach that combines data
from influenza infections of human volunteers with a mathematical
framework. We find that the initial generation of resistant cases is
most likely lower than the fraction of resistant cases reported.
However, our study also clearly shows that the results depend
strongly on the role the immune response plays, an issue that needs
to be addressed in future studies.
Neuraminidase Inhibitor Resistance in Influenzaestimated previously to be U0 ¼ 4 3 10
8 [23]. Performing an
independent estimate that assumes a surface area of the
upper respiratory tract of 100–200 cm
2 [34,35] and the size of
an epithelial cell of 1 5310
 7 cm
2 [36], we obtain values in
the same range. For sake of consistency with the earlier study,
we choose U0 ¼ 4 3 10
8. While this estimate comes with a
certain amount of uncertainty, for our purposes, knowing the
exact value for U0 is not critical since a different value would
simply lead to a rescaling of some of the parameter values.
Lastly, the constant k is set to k¼1 per day. It is only used to
make units consistent. Any change in k would only lead to a
rescaling of the immune response, which is given in arbitrary
units.
Stochastic Model of Infection Dynamics
Since resistant virions are initially not present and, upon
initial generation, are at low numbers, stochastic effects can
become important. It is therefore useful to also use stochastic
versions of the deterministic models described in the
previous section. One problem with using stochastic simu-
lations is the issue of units. With the deterministic models
introduced above, we are able to work in the experimentally
reported units of 50% tissue culture infectious doses per
milliliter (TCID50/ml) of nasal wash. However, if we want to
study the impact of stochastic effects, we need to convert to
numbers of infectious virions at the site of infection. Both
TCID50 measurements as well as our models only deal with
viable, infectious virions. Non-infectious viral particles, which
are known to be created in rather large quantities due to the
segmented nature of the inﬂuenza virus, can therefore be
ignored. Still, it is unclear how TCID50/ml of nasal wash
convert to numbers of infectious virions. At the minimum,
one TCID corresponds to a single infectious virion, but it is
more likely that on average more than one virion is needed to
establish an infected cell culture. We estimate that 1 100
virions correspond to one TCID. Next, virions/ml of nasal
Figure 1. Viral Titer (TCID50/ml of Nasal Wash)
Symbols in (A) and (B) are data from humans infected with influenza A/Texas/91 (H1N1). Early drug treatment starts at around 29 h, late treatment at
around 50 h post-infection. The dotted horizontal line shows the limit of assay sensitivity. The solid lines show total viral load as obtained from (A) the
target-cell depletion (TD) model and (B) the immune response (IR) model. The dashed lines show the resistant subpopulation. Further details on the
experimental data are given in [27].
doi:10.1371/journal.pcbi.0030240.g001
Table 2. Parameters for the Two Models Describing the within-Host Dynamics
Symbol Meaning Value (TD/IR Model) Comment
I(0) Initial number of infected cells 0 Assumed
Vr(0) Initial resistant viral load 0 Assumed
T Time of treatment start 0–4 days Assumed
U(0) Initial number of target cells 4 3 10
8 See text
l Mutation rate 10
 5 See text
c Fitness cost of resistance 0.1 See text
k Unit conversion constant 1 day
 1 See text
dI Infected cell death rate 1.3 3 10
0 /5 . 03 10
 1 days
 1 Fitted
dV Virus death rate 3.0 3 10
0 /8 . 13 10
 2 days
 1 Fitted
Vs(0) Initial sensitive viral load 1 3 10
 5 /7 . 73 10
 3 TCID50/ml Fitted
*
b Infection rate 6.3 3 10
 2 / 9.9 3 10
 2 ml/d   TCID50 Fitted
p Virus production rate 1.1 3 10
 5 / 1.2 3 10
 5 TCID50 /d   ml Fitted
X0 Initial immune response 0 / 3.4 3 10
 1 Fitted
r Immune response growth rate 0 / 1.0 days
 1 Fitted
a Antiviral efficacy 0.99 / 0.97 Fitted
TCID, tissue culture infectious dose.
*For the TD model, the value was bound from below at 10
 5. The reason for this is explained in the stochastic model section.
doi:10.1371/journal.pcbi.0030240.t002
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Neuraminidase Inhibitor Resistance in Influenzawash need to be converted to virions/ml at the site of
infection, which for uncomplicated inﬂuenza infections is
mainly the upper respiratory tract. Not much information is
available; based on circumstantial data ([37,38]), we estimate
that the concentration at the site of infection is higher by a
factor of 1 100. Finally, the volume of the upper respiratory
tract has been estimated to be about 30 ml [35]. Combining it
all, we obtain the very rough estimate that 1 TCID50/ml of
nasal wash corresponds to about 10
2–10
5 virions at the site of
infection. Calling this conversion factor c (with units of
(TCID50/ml)
 1), the variables of the deterministic model are
rescaled for the stochastic model according to V ! cV, p !
cp, b ! b/c. A smaller c leads to fewer virions in the stochastic
simulation, thereby increasing the importance of stochastic
effects.
An important issue is the fact that even for the largest
estimate of c, the best ﬁt value for the initial viral load in the
TD model (V0 ¼ 4.9 3 10
 7 TCID50/ml) corresponds to an
inoculum size of less than one virion. While some studies
suggest that a few virions are enough to start an infection,
clearly a value below one makes no sense. It is likely that the
initial estimate for V0 obtained from the model is wrong.
Indeed, experimental data from mice suggests that instead of
having minimum viral load at the start of infection, the viral
load ﬁrst drops over the course of a few hours, before it starts
to increase again [39]. Since the earliest data point available is
at 24 h post-infection, we cannot resolve such dynamics,
therefore leading to a likely underestimate for V0. Another
reason suggesting that the value for V0 obtained from the TD
model is too low comes from the fact that for the IR model,
the value of V0 is orders of magnitude larger. While this
indicates problems with the TD model, the data used here do
not allow us to conclusively reject it. We return to the
problem of model discrimination and lack of data in the
Discussion. To allow comparison between the deterministic
and stochastic versions of the TD model, we bound V0 by 10
 5
TCID50/ml from below. This leads to a ﬁt that is only a few
percent worse than the unbounded ﬁt, and by setting c¼10
5,
we can then compare deterministic and stochastic results in
the TD model. Further, to investigate the impact of a lower c,
we set c ¼ 10
3 for the IR model.
Numerical Implementation of the Models
The deterministic models are ﬁtted to the viral load data
using several ﬁtting routines (lsqnonlin, fmincon, and nlinﬁt)
provided by Matlab R2006b (The Mathworks). To obtain the
results shown below, we perform both stochastic and
deterministic simulations. The deterministic ODEs are
implemented in Matlab R2006b, the stochastic simulations
are written in Fortran 90. A purely stochastic simulation
(Gillespie algorithm) would be prohibitively slow, due to the
large numbers of cells/virions. Therefore, the simulation is
implemented using a partitioned leaping algorithm [40]. The
results shown for the stochastic simulations are averages over
1,000 or 5,000 runs. Since our focus is on stochastic effects of
the virus dynamics during resistance emergence, we treat the
immune dynamics in the IR model deterministically. All
programs are available from the authors upon request.
Results
Modeling Virus Shedding
The models described in the Materials and Methods section
provide us with viral load data during the course of the
infection. We can then relate viral load to the amount of viral
shedding. The amount of shedding depends on host
symptoms, such as sneezing or coughing. These symptoms
are caused by host response mechanisms, which in turn
depend on viral load [41]. To ﬁnd the relation between viral
load and shedding, we can use data from two recent studies
that report viral load as well as nasal discharge weight for
volunteers infected with inﬂuenza A/Texas/36/91 (H1N1)
[42,43]. By plotting nasal discharge as a function of viral
load, we can ﬁt a function to obtain an analytic relationship.
For low levels of virus, we expect few symptoms to occur,
resulting in low viral shedding. Once viral load reaches a
certain level, symptoms start to appear and shedding
increases. For high viral load, shedding will likely saturate.
We can model this using a sigmoid function, such as a four-







c2 þ c4: ð1Þ
Here, Vtot is the total viral load (both sensitive and resistant
virus). The best ﬁt values for the four parameters are found to
be c1¼6.1, c2¼4.8, c3¼2.6, and c4¼1.5. The data and best ﬁt
are shown in Figure 2. We also ﬁtted a linear function to the
data; however, the function given by Equation 1 produces a
statistically slightly better ﬁt (adjusted R
2 is 0.75 for the Hill
function and 0.73 for a linear model). We also prefer
Equation 1 on biological grounds, due to its threshold and
saturation effects for low and high viral load, respectively.
We then obtain the total amount of viral shedding by
multiplying virus concentration with the amount of discharge
at every time point and integrating over the duration of
infection. The equation for the total amount of shedding is
given by
Figure 2. Nasal Discharge Weight as a Function of Viral Load
Data are from [42] (squares) and [43] (circles). Also shown is the best fit
for the function s (Equation 1). Note that daily discharge is measured in
grams; we make the approximation that one gram corresponds to 1 ml
in volume.
doi:10.1371/journal.pcbi.0030240.g002
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Z
sðVtotÞVidt ð2Þ
where i¼r for the resistant and i¼s for the sensitive strain. It
is important to note that the amount of either sensitive or
resistant shedding depends on the total viral load of both
sensitive and resistant virus. In the following, we will consider
shedding of sensitive virus in the absence of treatment (Ss),
shedding of resistant virus during a treated infection started
by sensitive virus (St
r), and shedding of resistant virus during
an infection started by resistant virus (Sr).
Connecting Shedding with Epidemiological Parameters
The results obtained for viral shedding allow us to estimate
the two quantities of interest, the initial generation of
resistance and its subsequent spread through the population.
Both quantities can be expressed in terms of the average
number of new infections caused by an infected host, the
reproductive number, R [44]. The simplest relation between
R and shedding, S, is a direct proportionality, R ¼ kS. (In
Appendix A: Mapping Behavior to Viral Load, we discuss a
more detailed relation including a behavioral component.)
The parameter k describes the rate of transmission for the
sensitive (ks) or resistant (kr) strain. For the sensitive strain in
the absence of treatment and resistance, we have Rs ¼ ksSs.
The generation of resistance, Rt
r, can be expressed as the
expected number of resistant infections caused by trans-
mission of resistant virus (characterized by the transmission
rate kr) from a treated patient initially infected with sensitive
virus, who sheds resitant virus, St
r. This leads to Rt
r ¼ krSt
r. The
subsequent spread of resistance is expressed as the expected
number of resistant infections caused by a host initially
infected with only the resistant virus, Rr¼krSr. Figure 3 shows
these different processes schematically.
Estimates for the reproductive number of inﬂuenza (Rs) are
available and our framework allows us to determine the
amount of shedding, Ss. This allows calculation of the
transmission rate, ks. It is not clear how the ability to spread
as measured by ks or kr differs between sensitive and resistant
strains. Studies in ferrets have shown that transmissibility of
resistant strains varies, some resistant mutants are poorly
transmitted, while others seem to be as well transmitted as the
sensitive strain [14–16]. As a (likely very conservative) bound
for the potential of transmission between humans, we assume
in what follows that the resistant strain transmits as well as
the sensitive strain, i.e., kr ¼ ks. One can easily change this
assumption, the results scale accordingly. With this assump-
tion, we can then write Rr ¼ Sr




Ss Rs, allowing us to
determine the generation of resistance during treatment as
measured by Rt
r and its subsequent spread as measured by Rr.
The Generation of Resistance
We ﬁrst consider the generation of resistance during
treatment as described by Rt
r. To that end, we determine
shedding of sensitive virus in the absence of both antiviral
drug and resistant virus, Ss, as well as shedding in the presence
of treatment and resistant virus, St
r. Figure 4 shows the
generation of resistance as a function of treatment start,
antiviral efﬁcacy, ﬁtness cost, and mutation rate for the TD
and IR models for both deterministic and stochastic
simulations. For the shown results, we use a value of Rs ¼ 2,
in line with current estimates [45,46].
Several observations are notable. First, the results show that
more effective treatment, which better removes the sensitive
strain and thereby allows the resistant strain to grow,
increases the danger of resistance generation (Figure 4B). A
similar ﬁnding holds for the timing of treatment start (Figure
4A). Treatment that starts late has little impact on the
sensitive population, which prevents the resistant population
from reaching high numbers. Treatment that starts less than
two days after infection has an impact, and initially increases
the generation of resistance. Interestingly, the results
obtained for the IR model and the stochastic TD model
suggest that very early treatment can reduce the danger of
resistance generation. For the IR model, this is because if
treatment reduces the sensitive strain fast enough, the
immune response is able to quickly eradicate the remaining
resistant subpopulation. For the TD model, early treatment
can lead to eradication of the sensitive strain before any
resistant mutants are created, resulting in signiﬁcantly lower
levels of resistance generation compared to the deterministic
model, where resistant mutants are always created.
Second, a change in ﬁtness cost or mutation rate has little
impact on the TD model for a wide range of parameter values
but does affect the results for the IR model (Figure 4C and
4D). For the TD model, the stochastic results deviate from the
deterministic model for low mutation rates, again because
resistant mutants are often not created.
Figure 3. Schematic of Resistance Generation and Spread
doi:10.1371/journal.pcbi.0030240.g003
Figure 4. Generation of Resistance, as Measured by Rt
r, for the TD Model
(No Immune Response) and IR Model (with Immune Response)
Results are shown for both deterministic and stochastic simulations.
Unless varied, treatment starts 24 h post-infection, and the other
parameters are as shown in Table 2.
doi:10.1371/journal.pcbi.0030240.g004
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Neuraminidase Inhibitor Resistance in InfluenzaThird, the TD model consistently predicts values for
resistance generation above those for the IR model. This
can be understood as follows: in the TD model, the resistant
strain competes with the sensitive strain for resources (target
cells). In the presence of the sensitive strain, the resistant
strain is outcompeted. If the sensitive strain is removed, the
resistant strain will infect most target cells and reaches high
levels. In contrast, the immune response in the IR model acts
against both the sensitive and resistant strains. If sensitive
virus is suppressed by NI, the mounting immune response will
still act against the resistant strain, preventing it from
reaching high levels [47].
Fourth, stochastic effects become important either if
treatment occurs early and wipes out the sensitive population
before resistance has been created, or if mutation rates are
low. As mentioned in the Materials and Methods section, the
conversion factor from TCID to virions can only be estimated
rather broadly. If this factor is set to a lower value, the
importance of stochastic effects increases further (unpub-
lished data).
The Spread of Resistance
While the parameter governing the generation of resist-
ance is important, the parameter describing the subsequent
spread of resistance is arguably more important. Even if
generation of resistance is infrequent, only a few resistant
infecteds could be enough to start a resistant outbreak. The
possibility for such an outbreak is determined by Rr, the
number of secondary infections caused by a person infected
with resistant virus. To determine Rr, we performed
simulations assuming that the host is infected with only the
resistant strain. This allowed us to obtain Sr, and using the
previously obtained values for Ss, we can then compute Rr.I n
Figure 5, we plot Rr for the two models. If Rr , 1, chains of
transmission of resistant virus will stutter to extinction. The
results show that this is the case if the ﬁtness cost is at least
’25% for the IR model or at least ’45% for the TD model.
While some NA resistant mutants have been found to carry a
signiﬁcant within-host ﬁtness cost, other mutants are similar
in within-host ﬁtness to the wild-type strain [16,31], which
suggests that these mutants might have the potential to
spread—provided transmission of the sensitive and resistant
strains are equal (ks¼kr), something that seems to be the case
for some but not all resistant mutants [14–16]. While a value
of Rr . 1 can lead to an outbreak in a fully susceptible
population, during a pandemic the time at which resistance
appears will be crucial. If a signiﬁcant number of susceptible
hosts have already been infected with the sensitive strain, the
effective reproductive number might not be enough for a
subsequent, resistant outbreak [7,48]. However, once a
resistant strain has been created and spreads, it is possible
that further mutations occur. While back-mutations to the
ﬁtter, susceptible strain are possible, there is evidence that it
is often more likely that instead of reversion to the original
form, the resistant mutant undergoes further, so called
compensatory mutations [49,50]. These mutations reduce
the ﬁtness cost that comes with resistance, while at the same
time retaining the resistant mutation. The result can be a
strain that is at the same time resistant and has a ﬁtness
similar to the initial, sensitive strain. We have previously
considered some of the implications of compensatory
mutations on the spread of resistance through a population
[51]. Limited in vitro evidence suggests that compensatory
mutations might occur for NI resistant inﬂuenza [52].
Discussion
We have demonstrated that it is possible to combine data
from infected individuals with mathematical models to obtain
estimates for important between-host parameters, without
the need for epidemiological data.
The results we obtained suggest that to minimize the
danger of resistance generation, treatment at the very
beginning of the infection (i.e., prophylaxis) is best (Figure
4A). While this seems to reduce the changes of generating
resistance, once it has been generated, it is likely to spread, as
long as the ability of the resistant strain to transmit is similar
to that of the sensitive strain (Figure 5).
Unfortunately, several shortcomings currently do not allow
us to obtain precise results. The main problem is our lack of
understanding of the dynamics governing within-host inﬂu-
enza infections. Both the TD model without immunity and
the IR model with immunity are able to ﬁt the data; however,
the estimated parameters differ. Additionally, parameters
such as the conversion rate between TCID50 and number of
virions, or the rate of mutation, are based on estimates that
come with a signiﬁcant amount of uncertainty. The problem
of unrealistic parameter estimates, such as the very low initial
viral load obtained for the unbounded TD model, further
reinforce the fact that more data is needed to better
discriminate between models.
The inability to discriminate between models would not be
too problematic if the two different models produced similar
results. While the results are somewhat similar for the spread
of resistance, as well as the impact of treatment on the
Figure 5. Spread of Resistance as Measured by Rr
Note that only variation in the fitness cost has an impact on Rr since
treatment does not affect the resistant strain.
doi:10.1371/journal.pcbi.0030240.g005
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Neuraminidase Inhibitor Resistance in Influenzasensitive strain (see Appendix B: The Impact of Treatment on
the Spread of the Sensitive Strain), they differ signiﬁcantly
with regard to the initial generation of resistance (Figure 4).
Inclusion of an immune response reduces the danger of
resistance generation. Since there is no immunity in the TD
model, the results obtained from this model provide an upper
bound. We expect the ‘‘true’’ parameter values to be closer to
those of the IR model. While we believe that a model with an
included immune response is more accurate compared to the
TD model, it is by no means clear that an antibody-based
response is the most important component. Many studies
point toward the fact that innate, cellular, and humoral
immune responses all play important, potentially overlapping
roles to help clear the infection. In future studies, it will be
crucial to obtain more data for the within-host dynamics, to
allow for better model discrimination and a better under-
standing of the important drivers of the infection dynamics.
Such an improved understanding of the within-host dynamics
of inﬂuenza will likely require a tight combination of
experimental data with mathematical models [23,53].
Also needed are further studies that investigate the ability
of the resistant strains to transmit. Speciﬁcally, it is necessary
to understand if reduced transmission is due to reduced
shedding, reduced survival of the resistant strain during
transmission, or other factors such as changes in contact
rates. To that end, further studies in ferrets seem to be the
most promising approach.
While the lack of better data currently prevents us from
obtaining quantitative results, these limitations can be over-
come. Provided enough experimental data on within-host
dynamics and some transmission data between individuals
are available, the approach discussed here can produce
parameter estimates that can then be used to simulate and
study potential spread of novel emerging pathogens. Cru-
cially, this can be done before the pathogen has produced
outbreaks large enough to reliably obtain parameter esti-
mates from epidemiological data. Such an approach will be
important if we want to be one step ahead of NI resistant
inﬂuenza, a potential H5N1 outbreak, and other newly
emerging diseases for which epidemiological data are lacking.
In the best case, we will be able to prevent this data from ever
existing.
Appendix A: Mapping Behavior to Viral Load
In the previous text, we connected viral shedding and the
number of new infections by a simple proportionality, R¼kS.
Here we consider a more complicated mapping that includes
behavioral changes. A sick person might reduce the frequency
of contacts with other persons, for instance by staying at
home instead of going to work. Such a self-imposed
quarantine reduces the ability to infect other people. Since
contact reduction is likely dependent on the strength of
symptoms, we use symptom score as a proxy for behavior
[42,43]. If the symptom score is zero, an infected person ‘‘feels
ﬁne’’ and behaves as usual. As symptoms increase, the contact
rate is reduced. Unfortunately, there is no data that reports
how changes in symptom scores inﬂuence contact rates. We
therefore use the rather ‘‘ad hoc’’ relation w ¼ 1/( 1þ y)
between (normalized) contact rate, w, and symptom score, y.
With the right data available, one could improve this relation
by for instance introducing additional scaling constants, or by
choosing an entirely different mapping from symptoms to
behavior. Since such data is absent, the results obtained from
this approach should only be considered illustrative.
We can express the symptom score y as a function of viral
load V by ﬁtting a function y(V) to data reported in [42,43].
While symptom score is unlikely to depend exponentially on
viral load over a wide range, for the reported data we
obtained a good ﬁt for an exponential function given by y ¼
f1exp[f2log10(V)] with best ﬁt parameter values given by f1¼0.15
and f2¼0.77 (Figure 6). Also note that symptoms are unlikely
directly related to viral load, but instead are more likely to be
caused by depletion of target cells or the immune response.
We use viral load here as a proxy for those (unknown)
quantities, which allows us to use available data and present
the results in a closed framework.
We then obtain w as a function of viral load as
w ¼
1
1 þ f1ef2log10ðVÞ ; ð3Þ




The integral expression now represents shedding, adjusted
for behavioral changes. The constant k9i includes factors such
as survival of the strain outside the host. If we again assume k9s
¼k9r, we have R9r¼D9Rs and R9t







and an equivalent expression for D9
t. Figure 7 compares
results for Rt
r and R9t
r for the case of the IR model. One can
see that including the behavioral component only changes
results slightly. We found the same to be true for all the other
results presented (unpublished data).
Figure 6. Symptom Score as a Function of Viral Load
Data are system symptom score values and viral load from [42] (squares)
and [43] (circles). Also shown is the best fit for the function y.
doi:10.1371/journal.pcbi.0030240.g006
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the Sensitive Strain
While the main focus of this study is on the generation and
spread of NI resistant inﬂuenza, the framework can also be
used to study how treatment affects shedding and therefore
transmission of the sensitive strain, providing an approach
that is complementary to existing ones [54]. Ignoring the
resistant strain for this calculation, we deﬁne Rt
s as the
expected number of new infections created by an infected
patient who receives treatment. Figure 8 shows Rt
s as a
function of treatment start and antiviral efﬁcacy. As
expected, early treatment and high antiviral efﬁcacy can
signiﬁcantly reduce transmission. However, even for the
rather high antiviral efﬁcacies of 99% and 97%, respectively,
treatment within the ﬁrst ’48 h is required to reduce Rt
s
below one. To stop spread in a population, such early
treatment would need to be applied to almost every infected
person, something that is not feasible. This suggests that using
treatment alone is unlikely to stop an outbreak. Rather, a
combination of treatment, prophylaxis, vaccination, and
social distancing measures will be required to effectively
prevent the next pandemic, as has been noted previously
[55,56]. One additional interesting result seen in Figure 8 is
the fact that differences between the TD and IR models are
less pronounced compared with the results obtained for
resistance generation. This is because the presence or absence
of immune pressure has a stronger effect on the potential de
novo emergence of the resistant strain.
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